Diagnosis of Colorectal Cancer and Adenomatous Polyps of the Colon Based on the Level of MicroRNA Expression in the Mucous Membrane (Pilot Clinical Study)

The gold standard for colorectal cancer (CRC) diagnosis, colonoscopy with biopsy, is an invasive technique and has some limitations, while the known non-invasive methods do not possess sufficient sensitivity and specificity. The application of microRNA as a diagnostic and prognostic CRC biomarker may compensate for the colonoscopy limitations. However, there are no data in the literature on the existence of real test systems based on the evaluation of microRNA expression. Our pilot study is the first step to creating a test system for CRC diagnosis based on the analysis of microRNA expression in the tissue of the intact colon.

The aim of the study is to assess the prospects of using the level of microRNA expression as a supplemental method for diagnosing colorectal cancer and adenomatous polyps.

Materials and Methods. Patients participating in the study were divided into three groups: group 1 included patients with CRC (n=5), group 2 — patients with polyps in the colon (n=4), and patients without oncological pathology treated for hemorrhoidal disease without exacerbation (n=5) composed group 3.

Tissue samples of the intact gut were taken from all patients. In groups 1 and 2, biopsy was performed in the process of right-sided laparoscopic resection of the colon with tumor. Samples of the mucous membrane from the distal part of the rectum in patients of group 3 were also collected intraoperatively; they were operated on using Milligan–Morgan technique. In groups 1 and 2, CRC and polyp samples, respectively, were taken for the analysis additionally to the intact gut area.

The test panel included the following microRNAs: hsa-miR-10b-5p, hsa-miR-20a-5p, hsa-miR-141-3p, hsa-miR-181b-5p. The levels of the reference genes were analyzed with the help of real-time polymerase chain reaction using intercalating SYBR Green stain.

Results. Expression of hsa-miR-141-3p in the mucous membrane of the colon in patients of groups 1 and 2 (with CRC and polyps, respectively) was statistically significantly higher than in patients without bowel tumors. At the same time, the expression level of hsa-miR-10b-5p was statistically significantly lower in the tumor tissue (cancer or polyps) in comparison with patients of group 3.

Lower values of expression in all tested microRNAs have been detected in the CRC tissue relative to the intact mucosa of the same patients. A similar tendency was also observed in patients with adenomatous polyps.

Conclusion. The results of the study have shown that of four microRNAs, included into the test panel, hsa-miR-141-3p and hsa-miR-10b-5p were found to have the diagnostic value for identifying tumor colorectal lesions. Thus, our data will assume that supplementing the endoscopic tests of the large intestine by the epigenetic analysis of the mucous membrane is a promising approach to cancer screening procedures.

1. Morgan E., Arnold M., Gini A., Lorenzoni V., Cabasag C.J., Laversanne M., Vignat J., Ferlay J., Murphy N., Bray F. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 2023; 72(2): 338–344, https://doi.org/10.1136/gutjnl-2022-327736.
2. Knudsen A.B., Zauber A.G., Rutter C.M., Naber S.K., Doria-Rose V.P., Pabiniak C., Johanson C., Fischer S.E., Lansdorp-Vogelaar I., Kuntz K.M. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the us preventive services task force. JAMA 2016; 315(23): 2595–2609, https://doi.org/10.1001/jama.2016.6828.
3. van Dam L., Kuipers E.J., van Leerdam M.E. Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol 2010; 24(4): 479–492, https://doi.org/10.1016/j.bpg.2010.03.009.
4. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., Levin T.R., Lavin P., Lidgard G.P., Ahlquist D.A., Berger B.M. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370(14): 1287–1297, https://doi.org/10.1056/NEJMoa1311194.
5. Robertson D.J., Lee J.K., Boland C.R., Dominitz J.A., Giardiello F.M., Johnson D.A., Kaltenbach T., Lieberman D., Levin T.R., Rex D.K. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2017; 152(5): 1217–1237.e3, https://doi.org/10.1053/j.gastro.2016.08.053.
6. Wu Z., Li Y., Zhang Y., Hu H., Wu T., Liu S., Chen W., Xie S., Lu Z. Сolorectal cancer screening methods and molecular markers for early detection. Technol Cancer Res Treat 2020; 19: 1533033820980426, https://doi.org/10.1177/1533033820980426.
7. Issa I.A., Noureddine M. Colorectal cancer screening: an updated review of the available options. World J Gastroenterol 2017; 23(28): 5086–5096, https://doi.org/10.3748/wjg.v23.i28.5086.
8. Jain S., Maque J., Galoosian A., Osuna-Garcia A., May F.P. Optimal strategies for colorectal cancer screening. Curr Treat Options Oncol 2022; 23(4): 474–493, https://doi.org/10.1007/s11864-022-00962-4.
9. Polyanskaya E.A., Fedyanin M.Yu., Tryakin A.A., Tjulandin S.A. Colorectal cancer, screening: achievements и opportunities. Onkologicheskaya koloproktologiya 2018; 8(4): 11–29.
10. Teixeira C., Martins C., Dantas E., Trabulo D., Mangualde J., Freire R., Alves A.L., Cremers I., Oliveira A.P. Interval colorectal cancer after colonoscopy. Rev Gastroenterol Mex (Engl Ed) 2019; 84(3): 284–289, https://doi.org/10.1016/j.rgmx.2018.04.006.
11. Lee J.Y., Lee J.H. Post-colonoscopy colorectal cancer: causes and prevention of interval colorectal cancer. Korean J Gastroenterol 2020; 75(6): 314–321, https://doi.org/10.4166/kjg.2020.75.6.314.
12. Giannopoulou N., Constantinou C. Recent developments in diagnostic and prognostic biomarkers for colorectal cancer: a narrative review. Oncology 2023; 101(10): 675–684, https://doi.org/10.1159/000531474.
13. Gmerek L., Martyniak K., Horbacka K., Krokowicz P., Scierski W., Golusinski P., Golusinski W., Schneider A., Masternak M.M. MicroRNA regulation in colorectal cancer tissue and serum. PLoS One 2019; 14(8): e0222013, https://doi.org/10.1371/journal.pone.0222013.
14. Moghadamnia F., Ghoraeian P., Minaeian S., Talebi A., Farsi F., Akbari A. MicroRNA expression and correlation with mRNA levels of colorectal cancer-related genes. J Gastrointest Cancer 2020; 51(1): 271–279, https://doi.org/10.1007/s12029-019-00249-2.
15. Bagryantsev M.V., Samoylenko V.M., Ryabkov M.G., Bazaev A.V., Desortsev I.L., Bunova S.S., Batanov M.A., Kiseleva E.B. Epigenetic markers of colorectal cancer: clinical data analysis. Vestnik eksperimental’noy i klinicheskoy khirurgii 2021; 14(4): 316–324, https://doi.org/10.18499/2070-478X-2021-14-4-316-324.
16. geNorm. URL: https://genorm.cmgg.be/.
17. URL: https://www.gene-quantification.de/hkg.html.
18. Gopal P., Ahmed Z., Venkata Ravi Kant V., Rao G.V., Rebala P. Circulating tumor DNA for monitoring colorectal cancer: a prospective observational study to assess the presence of methylated SEPT9 and VIM promoter genes and its role as a biomarker in colorectal cancer management. Turk J Surg 2023; 39(2): 107–114, https://doi.org/10.47717/turkjsurg.2023.6038.
19. Deris Zayeri Z., Parsi A., Shahrabi S., Kargar M., Davari N., Saki N. Epigenetic and metabolic reprogramming in inflammatory bowel diseases: diagnostic and prognostic biomarkers in colorectal cancer. Cancer Cell Int 2023; 23(1): 264, https://doi.org/10.1186/s12935-023-03117-z.
20. Church T.R., Wandell M., Lofton-Day C., Mongin S.J., Burger M., Payne S.R., Castaños-Vélez E., Blumenstein B.A., Rösch T., Osborn N., Snover D., Day R.W., Ransohoff D.F.; PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014; 63(2): 317–325, https://doi.org/10.1136/gutjnl-2012-304149.
21. Huang Q., Song Q., Zhong W., Chen Y., Liang L. MicroRNA-10b and the clinical outcomes of various cancers: a systematic review and meta-analysis. Clin Chim Acta 2017; 474: 14–22, https://doi.org/10.1016/j.cca.2017.08.034.
22. Wang Y.H., Ji J., Weng H., Wang B.C., Wang F.B. MiR-139 in digestive system tumor diagnosis and detection: Bioinformatics and meta-analysis. Clin Chim Acta 2018; 485: 33–41, https://doi.org/10.1016/j.cca.2018.06.006.
23. Gu X., Jin R., Mao X., Wang J., Yuan J., Zhao G. Prognostic value of miRNA-181a/b in colorectal cancer: a meta-analysis. Biomark Med 2018; 12(3): 299–308, https://doi.org/10.2217/bmm-2016-0222.
24. Zhang Q., Wang Q., Sun W., Gao F., Liu L., Cheng L., Li Z. Change of circulating and tissue-based miR-20a in human cancers and associated prognostic implication: a systematic review and meta-analysis. Biomed Res Int 2018; 2018: 6124927, https://doi.org/10.1155/2018/6124927.
25. Niu X., Sun H., Qiu F., Liu J., Yang T., Han W. miR-10b-5p Suppresses the proliferation and invasion of primary hepatic carcinoma cells by downregulating epha2 [retracted in: Biomed Res Int 2024; 2024: 9834789, https://doi.org/10.1155/2024/9834789]. Biomed Res Int 2021; 2021: 1382061, https://doi.org/10.1155/2021/1382061.
26. Yoshida K., Yokoi A., Kitagawa M., Sugiyama M., Yamamoto T., Nakayama J., Yoshida H., Kato T., Kajiyama H., Yamamoto Y. Downregulation of miR‑10b‑5p facilitates the proliferation of uterine leiomyosarcoma cells: a microRNA sequencing‑based approach. Oncol Rep 2023; 49(5): 86, https://doi.org/10.3892/or.2023.8523.

Bagryantsev M.V., Yanyshev A.A., Ryabkov M.G., Abelevich A.I., Dezortsev I.L., Bazayev A.V. Diagnosis of Colorectal Cancer and Adenomatous Polyps of the Colon Based on the Level of MicroRNA Expression in the Mucous Membrane (Pilot Clinical Study). Sovremennye tehnologii v medicine 2024; 16(5): 45, https://doi.org/10.17691/stm2024.16.5.05